The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -230,321 |
| Depreciation and amortization | 2,616 |
| Share-based compensation expense | 12,898 |
| Net periodic pension benefit (gain) loss for the qualified pension plan | -58 |
| Other non-cash items | 1,020 |
| Other receivables | 2,025 |
| Operating lease right-of-use assets | 0 |
| Prepaid expenses | -561 |
| Other non-current assets | 587 |
| Trade and other payables | 20,560 |
| Operating lease liabilities | -1,222 |
| Accrued expenses and other current liabilities | 2,591 |
| Net cash flow used in operating activities | -196,007 |
| Purchase of short-term marketable debt securities | 265,374 |
| Proceeds from maturities of short-term marketable debt securities | 468,401 |
| Purchase of property and equipment | 35 |
| Net cash flow provided by (used in) investing activities | 202,992 |
| Proceeds from long-term debt, net of issuance costs | 73,022 |
| Issuance of class a ordinary shares, net of transaction costs | 72,395 |
| Stamp duty on capital injection from moonlake to moonlake ag | 0 |
| Proceeds from stock options exercised-Equity Incentive Plan | 480 |
| Proceeds from stock options exercised-Employee Stock Option Plan ESOP | 100 |
| Net cash flow provided by financing activities | 145,997 |
| Effect of movements in exchange rates on cash held | 1,109 |
| Net change in cash and cash equivalents | 154,091 |
| Cash and cash equivalents, beginning of period | 180,426 |
| Cash and cash equivalents, end of period | 334,517 |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)